Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Breast 1

Conditions

Platinum-Refractory Fallopian Tube Carcinoma 1

Interventions

Paclitaxel 20Carboplatin 20Bevacizumab 13Radiotherapy 12Cisplatin 11Cyclophosphamide 8olaparib 6niraparib 6Taxes 6pembrolizumab 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Biopsy 5talazoparib 4dostarlimab 4aldesleukin 4Specimen Handling 4Fulvestrant 4Doxorubicin 4fludarabine 3atezolizumab 3Topotecan 3Radiation 3NVP-BKM120 3Methods 3Metformin 3Letrozole 3Hyperthermic Intraperitoneal Chemotherapy 3Early Intervention, Educational 3Colposcopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × ASTX-660 × Gynecologic × Clear all
NCT06393751 2025-06-03

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
GynecologicSarcoma

Platinum-Refractory Fallopian Tube Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡